
    
      The secondary objectives of this study are to assess other pharmacokinetic characteristics of
      BIOD-105 and BIOD-107 and compare those to Humalog®, to assess other pharmacodynamic
      characteristics of BIOD-105 and BIOD-107 and compare those to Humalog®, and to evaluate the
      safety and tolerability of BIOD-105 and BIOD-107 compared to Humalog®.
    
  